Subsidiaries Silence EContact Us>
Silence Therapeutics Silence Therapeutics
▲
1.77p (+0.155p)
Vol: 991131
(15-minute delayed)
View full stock quote


  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi Hub
  • Menu
  • About Us
    • Overview
    • Strategy
    • History
    • Management
    • Board Of Directors
    • Scientific Advisory Board
  • RNAI Platform
    • Overview
    • Delivery Platform
    • RNAi Platform
    • RNA Interference
    • Intellectual Property
    • Publications
    • Glossary
  • Pipeline
    • Overview
    • Pre-Clinical development
  • Collaborations
    • Overview
    • Silence's Strengths
    • Partnerships
    • Partnering Opportunities
  • Investor Relations
    • Overview
    • Press Releases
    • Corporate Governance
    • Analyst Coverage
  • News & Events
    • Press Releases
    • Events
    • In the News
    • Publications
  • RNAi Hub
  • Contact
  • Press Releases
  • Corporate Governance
  • Analyst Coverage

  • Press Releases
  • Corporate Governance
  • Analyst Coverage

Analyst Coverage

Analyst Coverage

Nomura Code Securities
Samir Devani, European Biotech Analyst
1 Carey Lane
London
EC2V 8AE
Tel:+44 (0) 20 7776 1200

Hybridan
Sanjay Jha
29 Throgmorton Street
London
EC2N 2AT
Tel:+44 (0) 20 7947 4004

Singer Capital Markets
Shawn Manning
1 Hanover Street
London
W1S 1YZ
Tel:+44 (0) 20 3205 7500

pdf Hybridan's analysis of Silence Therapeutics Plc

Silence News

  • 17.05.12

    Silence Announce New Data from Phase I Study of Atu027 RNAi Therapy

  • 14.05.12

    Publication of 2011 Annual Report and Notice of AGM

  • 03.05.12

    Silence’s partner, Quark Pharmaceuticals, extends Pfizer agreement to develop RNAi compound

  • 21.03.12

    Unaudited Preliminary Results for the Year ended 31 December 2011

  • 21.03.12

    Silence Therapeutics Forms Scientific Advisory Board and Forms Two New Research Collaborations

  • 14.05.12Silence Twitter

    A copy of Silence Therapeutics' 2011 Annual Report can be found here: http://t.co/WNSe96kX Featuring 2011 highlights in #rnai
    3 days ago

  • 03.05.12Silence Twitter

    Interview with Silence's CEO Tony Sedgwick by @brr_mediauk regarding Pfizer-Quark announcement: http://t.co/x2awtWTV #pharma #RNAi
    14 days ago



Quick Links

  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi HUB
  • Site Map

Contact

The Royal Institution of Great Britain

21 Albemarle Street
London W1S 4BS
United Kingdom


Tel:+44 (0) 20 7491 6520
Fax:+44 (0) 20 7491 6521
Silence Therapeutics

Copyright © 2012 Silence Therapeutics.
All rights reserved.

Terms of Use
Forward-Looking Statement